Cyclacel Pharmaceuticals Inc (CYCC)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 CONNELL DRIVE BERKELEY HEIGHTS, NJ 07922

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies, including CLL and AML. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers and a concomitant regimen of sapacitabine and olaparib, a PARP inhibitor, in BRCA positive patients with breast cancer. CYC140, a PLK inhibitor, is in a Phase 1 first-in-human study in patients with advanced leukemias. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.

Data as of 2021-08-02 07:52:46 -0400
Market Cap45.801 Million Shares Outstanding9.234 Million Avg 30-day Volume85.695 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.354 52-week High/Low11.42 / 3.12 Next Earnings Date2021-08-11 Price to Cash FLow (P/CF) -12.0782
Data provided by IEX Cloud
View SEC Filings from CYCC instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 31 16 93.75% 17 (1.0%) 7 (0.41%) 142.86%
13F shares: 4.091 Million 1.64 Million 149.51% 2.86 Million 1.555 Million 83.94%
% Ownership 57.5916 33.7099 70.84% 40.2603 31.9664 25.95%
New Positions: 18 11 63.64% 12 7 71.43%
Increased Positions 7 1 600.0% 1
Closed Positions 3 3 0.0% 2 1 100.0%
Reduced Positions 4 1 300.0% 4
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CYCC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CYCC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HENNEY CHRISTOPHER S

  • Director
7,122 2021-06-15 1

SEMS LLOYD

  • Director
7,122 2021-06-15 1

HRADSKY GREGORY T.

  • Director
7,122 2021-06-15 1

BARKER SAM L

  • Director
7,134 2021-06-15 1

SPIEGEL ROBERT J.

  • Director
7,122 2021-06-15 1

WALKER KARIN L

  • Director
21,366 2021-06-15 3

SCHWARTZ BRIAN

  • Director
21,366 2021-06-15 3

ROMBOTIS SPIRO GEORGE PRESIDENT AND CEO

  • Officer
  • Director
0 2020-12-11 1

MCBARRON PAUL SEE REMARKS

  • Officer
  • Director
0 2020-12-11 1

KIRSCHBAUM MARK CHIEF MEDICAL OFFICER

  • Officer
0 2020-10-23 2

EASTERN CAPITAL LTD

PORTFOLIO SERVICES LTD.

DART KENNETH BRYAN

  • 10% Owner
No longer subject to file 2020-04-24 0

CHIAO JUDY V.P., CLIN. DEV. & REG. AFF.

  • Officer
0 2019-12-05 0

UPRICHARD DAVID C

  • Director
0 2019-05-29 0

BANHAM JOHN MICHAEL MIDDLECOTT

  • Director
0 2019-05-29 0

TANG KEVIN C

TANG CAPITAL MANAGEMENT LLC

TANG CAPITAL PARTNERS LP

  • 10% Owner
559,900 2017-02-23 0

BACOPOULOS NICHOLAS G

  • Director
0 2016-05-26 0

SPIEGELMAN DANIEL K

  • Director
0 2012-05-23 0

SOSNOWSKI ROBERT EDWARD VP, MARKETING & SALES

  • Officer
28,000 2011-12-06 0

MARXE AUSTIN W & GREENHOUSE DAVID M

  • 10% Owner
No longer subject to file 2011-09-22 0

MORGAN STANLEY

  • 10% Owner
No longer subject to file 2009-11-10 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2008-11-18 0

WOMELSDORF DR JOHN FRANCIS VP, BUSINESS DEVELOPMENT

  • Officer
0 2008-11-18 0

COLLINS WILLIAM GENERAL MANAGER

  • Officer
0 2008-04-04 0

MCVIE JOHN GORDON

  • Director
0 2008-02-19 0

LEGAULT PIERRE

  • Director
0 2008-02-19 0

REYES GREGORY SENIOR VP, RESEARCH

  • Officer
3,000 2007-12-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HRADSKY GREGORY T. - Director

2021-06-17 16:09:12 -0400 2021-06-15 A 2,374 a 2,374 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

SCHWARTZ BRIAN - Director

2021-06-17 16:07:23 -0400 2021-06-15 A 2,374 a 7,122 direct

SCHWARTZ BRIAN - Director

2021-06-17 16:07:23 -0400 2021-06-15 A 2,374 a 3,561 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

WALKER KARIN L - Director

2021-06-17 16:07:02 -0400 2021-06-15 A 2,374 a 7,122 direct

WALKER KARIN L - Director

2021-06-17 16:07:02 -0400 2021-06-15 A 2,374 a 3,561 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

BARKER SAM L - Director

2021-06-17 16:08:23 -0400 2021-06-15 A 4,748 a 4,748 direct

SEMS LLOYD - Director

2021-06-17 16:08:30 -0400 2021-06-15 A 2,374 a 2,374 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

SCHWARTZ BRIAN - Director

2021-06-17 16:07:23 -0400 2021-06-15 A 4,748 a 7,122 direct

HENNEY CHRISTOPHER S - Director

2021-06-17 16:07:55 -0400 2021-06-15 A 4,748 a 4,748 direct

WALKER KARIN L - Director

2021-06-17 16:07:02 -0400 2021-06-15 A 4,748 a 7,122 direct

SPIEGEL ROBERT J. - Director

2021-06-17 16:08:16 -0400 2021-06-15 A 4,748 a 4,748 direct

BARKER SAM L - Director

2021-06-17 16:08:23 -0400 2021-06-15 A 2,374 a 2,386 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

HRADSKY GREGORY T. - Director

2021-06-17 16:09:12 -0400 2021-06-15 A 4,748 a 4,748 direct

SCHWARTZ BRIAN - Director

2021-06-17 16:07:23 -0400 2021-06-15 A 1,187 a 3,561 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

HENNEY CHRISTOPHER S - Director

2021-06-17 16:07:55 -0400 2021-06-15 A 2,374 a 2,374 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

WALKER KARIN L - Director

2021-06-17 16:07:02 -0400 2021-06-15 A 1,187 a 3,561 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

SPIEGEL ROBERT J. - Director

2021-06-17 16:08:16 -0400 2021-06-15 A 2,374 a 2,374 direct 0.1605 5.1364 -16.3724 5.1364 6 -20.3852 30

SEMS LLOYD - Director

2021-06-17 16:08:30 -0400 2021-06-15 A 4,748 a 4,748 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 22:15:04 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 21:45:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 21:15:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 20:45:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 20:15:04 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 19:45:04 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 19:15:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 18:45:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 18:15:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 17:45:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 17:15:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 16:45:02 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 16:15:03 UTC -10.0492 10.1292 250000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 15:45:03 UTC -10.0492 10.1292 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 15:15:02 UTC -10.0492 10.1292 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 14:45:02 UTC -11.3482 11.4282 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 14:15:04 UTC -11.3482 11.4282 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 13:45:04 UTC -11.3482 11.4282 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 13:15:03 UTC -11.3482 11.4282 150000
CYCLACEL PHARMACEUTICALS INC CYCC 2021-08-05 12:45:03 UTC -11.3482 11.4282 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments